Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD)

NCT01494805 is registered in ClinicalTrials.gov with Lions Eye Institute, Perth, Western Australia as lead sponsor.

NCT NCT01494805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01494805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD)
Lead sponsor
Lions Eye Institute, Perth, Western Australia
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2011
Completion date
August 31, 2017
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related maculopathies, age-related maculopathy, eye diseases, macular degeneration, maculopathies,age-related, maculopathy,age-related, retinal degeneration, retinal neovascularization